Inovio Pharmaceuticals, Inc. Stock price

Equities

INO

US45773H4092

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
13.88 USD +6.52% Intraday chart for Inovio Pharmaceuticals, Inc. +28.64% +126.80%
Sales 2024 * 604K Sales 2025 * 8.03M Capitalization 324M
Net income 2024 * -99M Net income 2025 * -93M EV / Sales 2024 * 537 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 40.4 x
P/E ratio 2024 *
-3.6 x
P/E ratio 2025 *
-4.6 x
Employees 122
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.39%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Inovio Pharmaceuticals, Inc., Q4 2023 Earnings Call, Mar 06, 2024
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Oppenheimer Upgrades Inovio Pharmaceuticals to Outperform From Perform, $4 Price Target MT
Transcript : Inovio Pharmaceuticals, Inc. - Special Call
Inovio Pharmaceuticals, Coherus BioSciences to Collaborate on Potential Throat Cancer Treatment MT
INOVIO and Coherus Announces Clinical Collaboration to Advance Development of INO-3112 in Combination with LOQTORZI?? (toripalimab-Ttzi) CI
Inovio Pharmaceuticals Plans BLA Submission for INO-3107 for Recurrent Respiratory Papillomatosis Treatment MT
INOVIO Plans to Submit a BLA for INO-3107 as a Potential Treatment for RRP in Second Half of 2024 Under Accelerated Approval Program CI
Inovio Pharmaceuticals, Inc.(NasdaqCM:INO) dropped from NASDAQ Biotechnology Index CI
Transcript : Inovio Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 09, 2023
Inovio Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Inovio Shares Rise 8% After FDA Feedback for INO-3107 DJ
Inovio Pharmaceuticals Advised to File BLA for Drug Candidate to Treat Recurrent Respiratory Papillomatosis MT
Inovio Pharmaceuticals, Inc. Receives FDA Feedback That Data from Completed Phase 1/2 Trial of INO-3107 CI
Inovio Says US FDA Breakthrough Therapy Designation Received for Recurrent Respiratory Papillomatosis Drug Candidate MT
More news
1 day+6.52%
1 week+28.64%
Current month+56.66%
1 month+53.88%
3 months+125.52%
6 months+203.03%
Current year+126.80%
More quotes
1 week
10.79
Extreme 10.7901
14.69
1 month
8.35
Extreme 8.3486
14.69
Current year
4.73
Extreme 4.73
14.69
1 year
3.89
Extreme 3.888
14.69
3 years
3.89
Extreme 3.888
124.44
5 years
3.89
Extreme 3.888
405.48
10 years
3.89
Extreme 3.888
405.48
More quotes
Managers TitleAgeSince
Chief Executive Officer 58 19-03-24
Director of Finance/CFO 60 02-05-31
Chief Tech/Sci/R&D Officer - 07-01-31
Members of the board TitleAgeSince
Chairman 79 03-11-30
Director/Board Member 64 17-12-31
Director/Board Member 66 20-01-14
More insiders
Date Price Change Volume
24-03-28 13.88 +6.52% 894,445
24-03-27 13.03 +5.25% 292,412
24-03-26 12.38 -0.16% 590,612
24-03-25 12.4 +6.71% 558,729
24-03-22 11.62 +5.83% 558,456

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
13.88 USD
Average target price
19.25 USD
Spread / Average Target
+38.69%
Consensus
  1. Stock
  2. Equities
  3. Stock Inovio Pharmaceuticals, Inc. - Nasdaq